Profile data is unavailable for this security.
About the company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
- Revenue in USD (TTM)34.70m
- Net income in USD-233.11m
- Incorporated2012
- Employees173.00
- LocationAtara Biotherapeutics Inc2380 Conejo Spectrum St, Suite 200THOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 623-4244
- Fax+1 (302) 636-5454
- Websitehttps://www.atarabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
China Health Industries Holdings, Inc. | 117.28k | -1.51m | 64.88m | 32.00 | -- | -- | -- | 553.19 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Lantern Pharma Inc | 0.00 | -17.53m | 65.31m | 21.00 | -- | 1.83 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
CEL-SCI Corp | 0.00 | -29.95m | 65.53m | 43.00 | -- | 4.57 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Avrobio Inc | 0.00 | 30.31m | 66.44m | 13.00 | 2.14 | 0.7477 | 2.17 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Medicinova Inc | 1.00m | -8.41m | 66.70m | 13.00 | -- | 1.11 | -- | 66.70 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Personalis Inc | 74.15m | -92.61m | 67.52m | 223.00 | -- | 0.5536 | -- | 0.9106 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 67.54m | 173.00 | -- | -- | -- | 1.95 | -2.12 | -2.12 | 0.3016 | -0.817 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Celularity Inc | 14.79m | -181.41m | 67.74m | 225.00 | -- | 1.99 | -- | 4.58 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
BioXcel Therapeutics Inc | 1.76m | -153.05m | 67.93m | 74.00 | -- | -- | -- | 38.68 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
Intensity Therapeutics Inc | 0.00 | -15.13m | 68.15m | 5.00 | -- | 7.01 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -18.07m | 69.09m | 15.00 | -- | 1.20 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Rallybio Corp | 0.00 | -76.28m | 69.22m | 43.00 | -- | 0.7083 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Instil Bio Inc | 0.00 | -123.32m | 69.53m | 49.00 | -- | 0.3378 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
Checkpoint Therapeutics Inc | 68.00k | -52.32m | 70.02m | 23.00 | -- | -- | -- | 1,029.64 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 10.17m | 8.52% |
Redmile Group LLCas of 31 Mar 2024 | 9.26m | 7.76% |
Citadel Advisors LLCas of 31 Mar 2024 | 6.51m | 5.46% |
BofA Securities, Inc.as of 31 Mar 2024 | 6.43m | 5.39% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.14m | 5.14% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.92m | 4.12% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.90m | 4.11% |
Vestal Point Capital LPas of 31 Mar 2024 | 2.80m | 2.35% |
Acadian Asset Management LLCas of 31 Mar 2024 | 2.64m | 2.21% |
AQR Capital Management LLCas of 31 Mar 2024 | 2.63m | 2.20% |